233 related articles for article (PubMed ID: 36694230)
1. Epigenetic dysregulation-mediated COL12A1 upregulation predicts worse outcome in intrahepatic cholangiocarcinoma patients.
Tang Z; Yang Y; Zhang Q; Liang T
Clin Epigenetics; 2023 Jan; 15(1):13. PubMed ID: 36694230
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic deregulation of MLF1 drives intrahepatic cholangiocarcinoma progression through EGFR/AKT and Wnt/β-catenin signaling.
Tang Z; Yang Y; Chen W; Liang T
Hepatol Commun; 2023 Aug; 7(8):. PubMed ID: 37486965
[TBL] [Abstract][Full Text] [Related]
3. MUC13 promotes intrahepatic cholangiocarcinoma progression via EGFR/PI3K/AKT pathways.
Tiemin P; Fanzheng M; Peng X; Jihua H; Ruipeng S; Yaliang L; Yan W; Junlin X; Qingfu L; Zhefeng H; Jian L; Zihao G; Guoxing L; Boshi S; Ming Z; Qinghui M; Desen L; Lianxin L
J Hepatol; 2020 Apr; 72(4):761-773. PubMed ID: 31837357
[TBL] [Abstract][Full Text] [Related]
4. miR-885-5p inhibits proliferation and metastasis by targeting IGF2BP1 and GALNT3 in human intrahepatic cholangiocarcinoma.
Lixin S; Wei S; Haibin S; Qingfu L; Tiemin P
Mol Carcinog; 2020 Dec; 59(12):1371-1381. PubMed ID: 33052627
[TBL] [Abstract][Full Text] [Related]
5. Methyl-CpG binding protein MBD2 is implicated in methylation-mediated suppression of miR-373 in hilar cholangiocarcinoma.
Chen Y; Gao W; Luo J; Tian R; Sun H; Zou S
Oncol Rep; 2011 Feb; 25(2):443-51. PubMed ID: 21165562
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic upregulation of TET2 is an independent poor prognostic factor for intrahepatic cholangiocarcinoma.
Yamashita H; Tourna A; Akita M; Itoh T; Chokshi S; Ajiki T; Fukumoto T; Youngson NA; Zen Y
Virchows Arch; 2022 May; 480(5):1077-1085. PubMed ID: 34905094
[TBL] [Abstract][Full Text] [Related]
7. FUT8 is regulated by miR-122-5p and promotes malignancies in intrahepatic cholangiocarcinoma via PI3K/AKT signaling.
Chen F; Li Y; Aye L; Wu Y; Dong L; Yang Z; Gao Q; Zhang S
Cell Oncol (Dordr); 2023 Feb; 46(1):79-91. PubMed ID: 36348252
[TBL] [Abstract][Full Text] [Related]
8. Bioinformatics Analysis Identifies the Estrogen Receptor 1 (ESR1) Gene and hsa-miR-26a-5p as Potential Prognostic Biomarkers in Patients with Intrahepatic Cholangiocarcinoma.
Qin X; Song Y
Med Sci Monit; 2020 May; 26():e921815. PubMed ID: 32435051
[TBL] [Abstract][Full Text] [Related]
9. A metabolism-related 4-lncRNA prognostic signature and corresponding mechanisms in intrahepatic cholangiocarcinoma.
Zou W; Wang Z; Wang F; Li L; Liu R; Hu M
BMC Cancer; 2021 May; 21(1):608. PubMed ID: 34034689
[TBL] [Abstract][Full Text] [Related]
10. Downregulation of miR-451 in cholangiocarcinoma help the diagnsosi and promotes tumor progression.
Guo D; Wang Q; Huang J; Hu Z; Chen C; Zhang C; Lin F
BMC Mol Cell Biol; 2022 Nov; 23(1):46. PubMed ID: 36352360
[TBL] [Abstract][Full Text] [Related]
11. Profiling of downregulated blood-circulating miR-150-5p as a novel tumor marker for cholangiocarcinoma.
Wu X; Xia M; Chen D; Wu F; Lv Z; Zhan Q; Jiao Y; Wang W; Chen G; An F
Tumour Biol; 2016 Nov; 37(11):15019-15029. PubMed ID: 27658773
[TBL] [Abstract][Full Text] [Related]
12. Deubiquitinase OTUB2 promotes intrahepatic cholangiocarcinoma progression by stabilizing the CTNNB1-ZEB1 axis.
Wang J; Dong Y; Wei Z; Zhang Y; Wu N; Zhang C; Zhang Y; Zi R; Hao J; Liang H; Chen J
Exp Cell Res; 2023 Apr; 425(1):113537. PubMed ID: 36858343
[TBL] [Abstract][Full Text] [Related]
13. Exosomal miR-30a-5p promoted intrahepatic cholangiocarcinoma progression by increasing angiogenesis and vascular permeability in PDCD10 dependent manner.
Jiang W; Shi X; Sun L; Zhang Y; Kong X; Yang X; Yin Y; Li C; Li X
Int J Biol Sci; 2023; 19(14):4571-4587. PubMed ID: 37781039
[TBL] [Abstract][Full Text] [Related]
14. Molecular profiling of intrahepatic cholangiocarcinoma: the search for new therapeutic targets.
Oliveira DV; Zhang S; Chen X; Calvisi DF; Andersen JB
Expert Rev Gastroenterol Hepatol; 2017 Apr; 11(4):349-356. PubMed ID: 28162004
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive analysis of genomic mutation signature and tumor mutation burden for prognosis of intrahepatic cholangiocarcinoma.
Zhang R; Li Q; Fu J; Jin Z; Su J; Zhang J; Chen C; Geng Z; Zhang D
BMC Cancer; 2021 Feb; 21(1):112. PubMed ID: 33535978
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic regulation in the carcinogenesis of cholangiocarcinoma.
Chiang NJ; Shan YS; Hung WC; Chen LT
Int J Biochem Cell Biol; 2015 Oct; 67():110-4. PubMed ID: 26100596
[TBL] [Abstract][Full Text] [Related]
17. An immunostaining panel of C-reactive protein, N-cadherin, and S100 calcium binding protein P is useful for intrahepatic cholangiocarcinoma subtyping.
Akita M; Sawada R; Komatsu M; Suleman N; Itoh T; Ajiki T; Heaton N; Fukumoto T; Zen Y
Hum Pathol; 2021 Mar; 109():45-52. PubMed ID: 33321161
[TBL] [Abstract][Full Text] [Related]
18. New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogramming.
Colyn L; Alvarez-Sola G; Latasa MU; Uriarte I; Herranz JM; Arechederra M; Vlachogiannis G; Rae C; Pineda-Lucena A; Casadei-Gardini A; Pedica F; Aldrighetti L; López-López A; López-Gonzálvez A; Barbas C; Ciordia S; Van Liempd SM; Falcón-Pérez JM; Urman J; Sangro B; Vicent S; Iraburu MJ; Prosper F; Nelson LJ; Banales JM; Martinez-Chantar ML; Marin JJG; Braconi C; Trautwein C; Corrales FJ; Cubero FJ; Berasain C; Fernandez-Barrena MG; Avila MA
J Exp Clin Cancer Res; 2022 May; 41(1):183. PubMed ID: 35619118
[TBL] [Abstract][Full Text] [Related]
19. Multiomics analysis reveals metabolic subtypes and identifies diacylglycerol kinase α (DGKA) as a potential therapeutic target for intrahepatic cholangiocarcinoma.
Liu W; Wang H; Zhao Q; Tao C; Qu W; Hou Y; Huang R; Sun Z; Zhu G; Jiang X; Fang Y; Gao J; Wu X; Yang Z; Ping R; Chen J; Yang R; Chu T; Zhou J; Fan J; Tang Z; Yang D; Shi Y
Cancer Commun (Lond); 2024 Feb; 44(2):226-250. PubMed ID: 38143235
[TBL] [Abstract][Full Text] [Related]
20. MiR-145 functions as a tumor suppressor targeting NUAK1 in human intrahepatic cholangiocarcinoma.
Xiong X; Sun D; Chai H; Shan W; Yu Y; Pu L; Cheng F
Biochem Biophys Res Commun; 2015 Sep; 465(2):262-9. PubMed ID: 26255969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]